U.S. markets closed
  • S&P Futures

    3,731.00
    -1.00 (-0.03%)
     
  • Dow Futures

    29,741.00
    -9.00 (-0.03%)
     
  • Nasdaq Futures

    11,542.75
    -13.00 (-0.11%)
     
  • Russell 2000 Futures

    1,721.40
    +0.60 (+0.03%)
     
  • Crude Oil

    82.30
    +0.15 (+0.18%)
     
  • Gold

    1,664.80
    -5.20 (-0.31%)
     
  • Silver

    18.83
    -0.05 (-0.29%)
     
  • EUR/USD

    0.9690
    -0.0049 (-0.50%)
     
  • 10-Yr Bond

    3.7050
    -0.2590 (-6.53%)
     
  • Vix

    30.18
    -2.42 (-7.42%)
     
  • GBP/USD

    1.0809
    -0.0077 (-0.71%)
     
  • USD/JPY

    144.2440
    +0.1220 (+0.08%)
     
  • BTC-USD

    19,555.32
    +573.47 (+3.02%)
     
  • CMC Crypto 200

    447.21
    +18.43 (+4.30%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,414.44
    +240.46 (+0.92%)
     

Fisher & Paykel Healthcare (NZSE:FPH) shareholders have earned a 12% CAGR over the last five years

·3 min read

When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying the right stocks can give your wealth a significant boost. For example, the Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) share price is up 64% in the last 5 years, clearly besting the market return of around 12% (ignoring dividends).

So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.

Check out our latest analysis for Fisher & Paykel Healthcare

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Over half a decade, Fisher & Paykel Healthcare managed to grow its earnings per share at 17% a year. The EPS growth is more impressive than the yearly share price gain of 10% over the same period. Therefore, it seems the market has become relatively pessimistic about the company.

The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).

earnings-per-share-growth
earnings-per-share-growth

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

What About Dividends?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Fisher & Paykel Healthcare's TSR for the last 5 years was 79%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments!

A Different Perspective

While the broader market lost about 12% in the twelve months, Fisher & Paykel Healthcare shareholders did even worse, losing 37% (even including dividends). However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. On the bright side, long term shareholders have made money, with a gain of 12% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Most investors take the time to check the data on insider transactions. You can click here to see if insiders have been buying or selling.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on NZ exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here